Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To this end, 13 women underwent GnRH agonist-induced gonadal down-regulation followed by graded transdermal addback of E(2) or Pl and randomly ordered iv infusions of saline or paired secretagogues on separate morning fasting.

Who Took Part

The abstract describes 13 women taking part.

By PubMed's age tags, the people studied were adults, women only.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

GH secretion was assessed by frequent blood sampling, immunochemiluminometry, and variable-waveform deconvolution analysis.

What Was Measured

Topics PubMed links to this paper include Administration, Cutaneous, Endocrine System, Estradiol, Growth Hormone-Releasing Hormone, Human Growth Hormone, Insulin-Like Growth Factor I and Premenopause.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 13 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.